Zhang, Fu-quan <br/><br/>
JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.  [electronic resource] 

 -  Oncotarget  Jun 2015 
 - 14329-43 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.3685  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>ErbB Receptors--genetics<br/>Erlotinib Hydrochloride--pharmacology<br/>Female<br/>Humans<br/>Janus Kinase 2--antagonists & inhibitors<br/>Lung Neoplasms--drug therapy<br/>Mice<br/>Mice, Nude<br/>Pyrrolidines--pharmacology<br/>Sulfonamides--pharmacology<br/>Xenograft Model Antitumor Assays